Multicentre, Open-label, Randomized Phase II Study of Vidaza (Azacitidine) Versus Supportive Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 International Prognostic Scoring System(IPSS )) Without the 5q Deletion Anaemia and Transfusion requirements.
Phase of Trial: Phase II
Latest Information Update: 02 Mar 2016
At a glance
- Drugs Azacitidine (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms ABRAZA
- 25 Jan 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 21 Apr 2011 New trial record